There had been fears the G-strain, within the main protein on the surface of the virus, would negatively impact on vaccines under development.
However, the research by Australia's national science agency the Commonwealth Scientific and Industrial Research Organisation (CSIRO), found no evidence the change would adversely impact the efficacy of vaccine candidates.
The study, published in the journal npj Vaccines, tested blood samples from ferrets given a candidate vaccine against virus strains that either possessed or lacked this mutation known as 'D614G'.
"This is good news for the hundreds of vaccines in development around the world, with the majority targeting the spike protein as this binds to the ACE2 receptors in our lungs and airways, which are the entry point to infect cells," said Professor Seshadri Vasan, who holds an honorary chair in Health Sciences at the University of York.
"Despite this D614G mutation to the spike protein, we confirmed through experiments and modelling that vaccine candidates are still effective, Vasan said in a statement.
"We've also found the G-strain is unlikely to require frequent 'vaccine matching' where new vaccines need to be developed seasonally to combat the virus strains in circulation, as is the case with influenza," he said.
CSIRO Chief Executive Larry Marshall said the research was critically important in the race to develop a vaccine.
"This brings the world one step closer to a safe and effective vaccine to protect people and save lives, Marshall said. he said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.